{
  "eval_id": "S38",
  "eval_file": "evals/single/S38.json",
  "timestamp": "2025-09-18T17:14:56.253831+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Patient HR+/HER2- progressed after CDK4/6; what key label-based caveats should I discuss?",
  "model_output": "For HR+/HER2- patients who progressed after CDK4/6, label-based options depend on prior endocrine and chemo exposure, performance status, and visceral involvement. It's important to review the EMA SmPC for each therapy to ensure on-label use and discuss expected efficacy and safety in this context. Please send the relevant SmPC sections by email for precise reference."
}